SHANGHAI, TAIPEI and SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research,...
Hence then, the article about hanchorbio and wuxi biologics enter strategic partnership to advance next generation bi and multi functional fusion protein pipeline was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline )
Also on site :
- Country Icon Carrie Underwood’s Latest Career Announcement May Leave Fans Disappointed
- Here's What Airlines Owe You if Your Flight Was Canceled or Delayed During This Weekend's Winter Snowstorm
- Ferry with 342 aboard sinks in the Philippines (VIDEO)